Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Vital Spark, a Spark Biomedical Podcast: Neurostimulation for Opioid Withdrawal Relief

The last three years have seen a dramatic rise in opioid-related deaths. In 2018, there were 42,000 deaths related to opioids. That number rose 57% to 73,757 in the year-long period between April 2020 and April 2022. One of the primary reasons many keep using opioids is fear of withdrawal. In the first episode of…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Vital Spark, a Spark Biomedical Podcast: Neurostimulation for Opioid Withdrawal Relief

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The last three years have seen a dramatic rise in opioid-related deaths. In 2018, there were 42,000 deaths related to opioids. That number rose 57% to 73,757 in the year-long period between April 2020 and April 2022. One of the primary reasons many keep using opioids is fear of withdrawal. In the first episode of the Vital Spark series, Daniel Powell, CEO of Spark Biomedical, joined Host Daniel Litwin to explain his company’s alternative opioid withdrawal treatment approach.

Powell suggested that a critical aspect of helping individuals and their families is to provide up-to-date education, resources, and accurate information—which is why the company is launching its podcast VitalSpark. Powell stated, “Addiction normally is coming from a place of trauma, normally coming from a place of someone trying to heal but not have the resources, so they’re coping.” Spark is offering a treatment option and now adding resources to ensure patients and their families are armed with the best information possible.

Spark Biomedical offers a solution to supplement traditional drug-based opioid withdrawal therapies through its wearable neurostimulation device, the Sparrow™Therapy System. This drug-free treatment option uses transcutaneous auricular neurostimulation (tAN®)and is applied to the skin on and around the ear tostimulatethe trigeminal and Vagus nerves that surface just below the skin in these areas. Worn by patients thorough the five-to-ten-day withdrawal period, this FDA-cleared treatment option has been clinically proven to significantly reduce acute withdrawal symptoms within 30 to 60 minutes of active use.

The company also has its sights set on understanding how its Sparrow Therapy wearable neurostimulation solution can impact PTSD and improve cognition, among other profound effects.More specifically,Spark recently kicked off a Phase II clinical trial to study the effect wearable neurostimulation can have on long-term addiction.Powell stated, “The overall goal has always been to be a recovery tool for long-term addiction.” He added, “After you get through withdrawal and what we’re starting clinical trials on, is can we manage your cravings, your depression, your anxiety, the triggers for relapse and actually fix the curve and start to bend the curve of addiction in America?”

Powell’s advice for supporters of addicted individuals? Don’t try to fix them. Have compassion for them and their journey. And, if they need support for opioid withdrawal, have them ask their care provider about the Sparrow Therapy System.”For more information on this topic, follow Spark Biomedical’s LinkedIn account and visit sparkbiomedical.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512